For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
We use cookies to make our site as useful as possible.
Our Cookie Policy explains how you can opt-out of the cookies we use.
If you continue without changing your cookie settings, we'll assume you’re happy with this.
Thanks for your reply. However, I noticed some contradictions between your discussion and one previous answer in the “Scientific Support” section of ab40760. Posted on 09-November-2006, it said “In regards to ab40760, the immunogenic peptide sequence is proprietary information. However, I can state that it is a 10aa peptide within aa630 - aa700 of the human adducin protein.” I checked the alignment at aa630 - aa700, and found that any 10aa peptide should not result in significant sequence overlap between alpha, beta, and gamma isoforms. Could you please help me find out why this contradiction occurred?
Abcam community
Verified customer
Asked on Jun 20 2012
Thank you for your reply.
I have had the opportunity to view the exact immunogen sequence used for this product. While the exact information is considered proprietary, I can confirm that this immunogen is based on a region spanning aa 710 through to the C-terminus. I have not found why the post you found from 2006 mentions a different region.
I hope this information is helpful to you. Please do not hesitate to contact us if you need any more advice or information.
Use our products? Submit an Abreview. Earn rewards!
https://www.abcam.com/abreviews
Answered on Jun 20 2012